Facebook Twitter LinkedIn


The science and practice of human immunology

The science and practice of human immunology

Letter From the President

Dear Colleagues:Notarangelo

I would like to begin this letter by extending my warmest wishes to you and your families during this holiday season. With hectic schedules and other matters guiding your thoughts, your dedication to the CIS and our cause is more impressive and appreciated than ever. There was much to be grateful for in 2016, but we are certainly looking forward to the continuous growth and progress that is to come in 2017.

To highlight some of the accomplishments of 2016, I would like to first acknowledge the CIS Advocacy Committee and the opportunities that they have been able to present to our membership. Most notably, the 2016 Physician Survey done in conjunction with the Immune Deficiency Foundation (IDF) as well as the committee’s white paper, currently in its final stages, on the use of genetic testing for PID patients. I look forward to the publication of this work which outlines the challenges that providers face when ordering genetic testing, the use and limitations of genetic testing, as well as a summary of recommendations for the use of genetic testing. These are important topics that relate to each of us on some level and represent the support that CIS is striving to provide to our important work.

Secondly, I would like to acknowledge the newly ratified International Alliance for Primary Immunodeficiency Societies (IAPIDS). The increase of intercontinental relationships has been a goal of the CIS leadership since inception, and it has finally come to fruition in the form of an international partnership with five international societies. The agreement between the Asia-Pacific Society of Immunodeficiencies (APSID), African Society for Immunodeficiencies (ASID), European Society for Immunodeficiencies (ESID), the Latin American Society for Immunodeficiencies (LASID), as well as the CIS was signed and announced at the ESID Annual Meeting in Barcelona, Spain on September 21, 2016.

The creation of the IAPIDS is an extraordinary accomplishment in global collaboration for the CIS that only serves to further the mission of all of its members with the ultimate goal of promoting excellence in education, research and patient care. The IAPIDS exists in order to advance the education of those engaged in the care of PID patients and promote member societies in disseminating and advancing the basic, translational and clinical science of PID and related knowledge all in the name of advancing the well-being and care of patients affected by PID and related conditions. Increased communication and collaboration amongst continental PID societies will only help make our small world smaller still for the benefit of all those involved.

The 2017 Annual Meeting is fast approaching, and as posters are finalized and speakers are confirmed, our appreciation for all of your enthusiasm and dedication to making the CIS meeting a premier educational program is heartfelt. I would personally like to thank all of those who submitted an abstract for review for the upcoming meeting. Each year the science submitted is increasingly impressive, and we are all in for quite a treat this coming March.

With that being said, I would like to encourage each and every one of you to join us at the Annual Meeting in Seattle, Washington. We are very excited to share more details about the extraordinary program in coming weeks, and hope you are able to join us for our new (and well-seasoned) sessions. One in particular that I would like to reference is the newly introduced Summer School: Second Edition. Because of the huge success that the Summer School has brought, we wanted to provide the same interesting and passionate discussions that occur at the regular Summer School to those of you who will be in Seattle. Please come and join us for this event! You can register for the Summer School: Second Edition as well as the Annual Meeting on the CIS website.

As we transition into this new year, it is important to reflect on our endeavors. I am very much aware that these would not be possible without the unwavering dedication of our membership and those of you who continue to strive to make this society vibrant and meaningful. I would like to commend you all for your devotion to the CIS and the success that we have already reached. Again, Happy New Year to you, and I hope to see you in Seattle!


Jordan S. Orange, MD, PhD
CIS President